Seelos Therapeutics to Participate in Two Investor Conferences
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a biopharmaceutical company focused on central nervous system disorders, is set to participate in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a biopharmaceutical company focused on central nervous system disorders, is set to participate in two upcoming investor conferences. The Guggenheim Healthcare Talks will occur on November 15-16, featuring 1x1 meetings hosted by CEO Raj Mehra and a fireside chat on November 16 at 2:20 PM ET. Additionally, Seelos will participate in The Benchmark Company 10th Annual Discovery on December 2, where Dr. Mehra will host virtual meetings. These events aim to enhance engagement with investors and provide insights into their advancing clinical pipeline.
Details
News Market Reaction – SEEL
The recorded move for SEEL in the trading session of this news was +0.88%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Nov. 2, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the Guggenheim Healthcare Talks, Idea Forum, 3rd Annual Neuro/Immunology Day on November 15-16th and in The Benchmark Company 10th Annual Discovery One on One Investor Conference on December 2nd, 2021.
Guggenheim Healthcare Talks, Idea Forum, 3rd Annual Neuro/Immunology Day
- Raj Mehra, Ph.D., Chairman and CEO, will host 1x1 meetings virtually on Monday and Tuesday, November 15-16th
- Yatin Suneja, Senior Biotechnology Analyst at Guggenheim Securities, LLC will host a fireside chat with Dr. Mehra on Tuesday, Nov. 16th at 2:20pm ET
- For conference and fireside chat registration visit: https://guggenheim-neuro-immuno-conference-2021.videoshowcase.net/login
The Benchmark Company 10th Annual Discovery One on One Investor Conference
- Raj Mehra, Ph.D., Chairman and CEO, will host 1x1 and small group meetings virtually on Thursday December 2nd
- For registration and more information email: events@benchmarkcompany.com
About Seelos Therapeutics:
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), Amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson's Disease, other psychiatric and movement disorders plus orphan diseases.
For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.
Contact Information:
Anthony Marciano
Chief Communications Officer
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
View original content to download multimedia:https://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-two-investor-conferences-301413478.html
SOURCE Seelos Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.